Startup entity

Psyence Biomedical Ltd.

Company PBM

All 1 tracked stories fall under one category: funding. Ibogaine is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 7.3 in the same window.

Last mentioned: Feb 21, 2026

Entity pulse

Recent coverage · Psyence Biomedical Ltd.

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Psyence Biomedical Ltd.

All 1 tracked stories fall under one category: funding. Ibogaine is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 7.3 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. Psyence Biomedical Ltd. appears in 1 tracked Startup story from February 21, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 34 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Psyence Biomedical Ltd.. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Put Option Exercised

    PsyLabs Ltd. formally exercises its rights under the Put Option Agreement with Psyence BioMed.

  2. Strategic Investment Announced

    Psyence BioMed announces it will make an equity investment in PsyLabs at fair market value.

Stories mentioning Psyence Biomedical Ltd. 1

Funding Rounds Neutral

Psyence BioMed to Invest in PsyLabs Following Put Option Exercise

Psyence Biomedical Ltd. (Nasdaq: PBM) has announced a strategic equity investment in PsyLabs Ltd. after the manufacturer exercised its rights under a previously established put option agreement. This move strengthens the relationship between the biopharmaceutical developer and its primary supplier of nature-derived psychedelic compounds.

2 sources

Psyence Biomedical Ltd. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.